{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:39:54Z","timestamp":1785901194562,"version":"3.56.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jgar.2017.09.015","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T16:15:56Z","timestamp":1506615356000},"page":"104-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Sulfamethoxazole\/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections"],"prefix":"10.1016","volume":"12","author":[{"given":"Lucas","family":"Watson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Esterly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley O.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Postelnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8748-185X","authenticated-orcid":false,"given":"Milena","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2017.09.015_bib0005","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00005792-200205000-00006","article-title":"Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study","volume":"81","author":"del Toro","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jgar.2017.09.015_bib0010","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/jac\/dkn301","article-title":"Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review","volume":"62","author":"Falagas","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.09.015_bib0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/CMR.00019-11","article-title":"Stenotrophomonas maltophilia: an emerging global opportunistic pathogen","volume":"25","author":"Brooke","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2017.09.015_bib0020","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1128\/AAC.01324-13","article-title":"Monotherapy with fluoroquinolone or trimethoprim\u2013sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.09.015_bib0025","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/AAC.01682-13","article-title":"Can levofloxacin be a useful alternative to trimethoprim\u2013sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?","volume":"58","author":"Cho","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.09.015_bib0030","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. Document M100-S25","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.jgar.2017.09.015_bib0035","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1179\/joc.2008.20.1.38","article-title":"Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?","volume":"20","author":"Galles","year":"2008","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2017.09.015_bib0040","doi-asserted-by":"crossref","first-page":"e0152132","DOI":"10.1371\/journal.pone.0152132","article-title":"Evaluation of trimethoprim\/sulfamethoxazole (SXT), minocycline, tigecycline, moxifloxacin, and ceftazidime alone and in combinations for SXT-susceptible and SXT-resistant Stenotrophomonas maltophilia by in vitro time-kill experiments","volume":"11","author":"Wei","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2017.09.015_bib0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2169\/internalmedicine.56.6141","article-title":"Clinical characteristics of Stenotrophomonas maltophilia bacteremia: a regional report and a review of a Japanese case series","volume":"56","author":"Ebara","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.jgar.2017.09.015_bib0050","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jhin.2012.02.008","article-title":"Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review","volume":"81","author":"Garazi","year":"2012","journal-title":"J Hosp Infect"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517301819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517301819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:54:32Z","timestamp":1761990872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716517301819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":10,"alternative-id":["S2213716517301819"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2017.09.015","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sulfamethoxazole\/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2017.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}